Oxford BioDynamics Plc (LON:OBD) CSO Dr Alexandre Akoulitchev explains to DirectorsTalk how the OBD work on ALS published in EBioMedicine fits into the bigger picture around this disease, the nature of the biomarkers and their relation to ALS, how quickly they could you predict ALS and the next plans for OBD technology in the ALS field.
Oxford BioDynamics Plc is a biotechnology company focused on the discovery and development of epigenetic biomarkers for use within the pharmaceutical and biotechnology industry. The Company’s award-winning, proprietary technology platform, EpiSwitch™, aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine.
In particular, EpiSwitch™ can reduce time to market, failure rates and the costs at every stage of drug discovery. Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re‐positioning programmes, and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.